Slide 1
... OPIOID TOXICITY IS RELATED TO OPIOID RECEPTORS IN NON-NOCICEPTIVE PATHWAYS AND COUNTER-OPIOID RESPONSES ...
... OPIOID TOXICITY IS RELATED TO OPIOID RECEPTORS IN NON-NOCICEPTIVE PATHWAYS AND COUNTER-OPIOID RESPONSES ...
Optimising Opioid Substitution Therapy
... Some advocate crushing the tablets, though this is an unlicensed approach Used for maintenance and detoxification Partial agonist, also has antagonist activity so may initially cause withdrawal from other opioids if started too early Blockade effect on other opioids during treatment- if dose suffici ...
... Some advocate crushing the tablets, though this is an unlicensed approach Used for maintenance and detoxification Partial agonist, also has antagonist activity so may initially cause withdrawal from other opioids if started too early Blockade effect on other opioids during treatment- if dose suffici ...
2016 BSMC syllabus - Friday - Therapeutics Education Collaboration
... as effective as 125 mg for heartburn relief ...
... as effective as 125 mg for heartburn relief ...
Product Monograph
... correlate with the dose and the concentration of LIXIANA. As a result of FXa inhibition, LIXIANA also prolongs clotting time in tests such as prothrombin time (PT), and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, a ...
... correlate with the dose and the concentration of LIXIANA. As a result of FXa inhibition, LIXIANA also prolongs clotting time in tests such as prothrombin time (PT), and activated partial thromboplastin time (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, a ...
SUMMARY OF PRODUCT CHARACTERISTICS
... depression of central nervous system ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, confusion, and lethargy; in more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression and coma. Overdose usually is not dangerous to life, in case i ...
... depression of central nervous system ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, confusion, and lethargy; in more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression and coma. Overdose usually is not dangerous to life, in case i ...
File - 911 Tactical Medicine
... Action: is a hypnotic drug without analgesic activity. It produces hypnosis characterized by rapid onset of action, usually within 1 minute. Dose: Adults: (10 and older) 0.3mg/kg (max dose: 20mg) IV Infused over 30 to 60 seconds will produce rapid sedation that lasts 10 to 15 minutes. Pediatrics: DO ...
... Action: is a hypnotic drug without analgesic activity. It produces hypnosis characterized by rapid onset of action, usually within 1 minute. Dose: Adults: (10 and older) 0.3mg/kg (max dose: 20mg) IV Infused over 30 to 60 seconds will produce rapid sedation that lasts 10 to 15 minutes. Pediatrics: DO ...
side effect
... Stepwise approach for managing infants and young children (<5 years Severity class ...
... Stepwise approach for managing infants and young children (<5 years Severity class ...
Pharmaceuticals and Women - WHO archives
... reproduction technology is relatively low in Central and Eastern Europe and North America.2 The UN Report World Contraceptive Use 2003 showed that the overall use of the contraceptive pill in North America is 15.5%, whereas in Western Europe about half of females in their reproduction ages are using ...
... reproduction technology is relatively low in Central and Eastern Europe and North America.2 The UN Report World Contraceptive Use 2003 showed that the overall use of the contraceptive pill in North America is 15.5%, whereas in Western Europe about half of females in their reproduction ages are using ...
Product Monograph
... experiences were observed in 33 patients. One patient was reported to have chest pain with possible ischemic ECG changes following a single dose of 10 mg. Postmarketing Experience with MAXALT® Serious cardiovascular events have been reported in association with the use of MAXALT®. The uncontrolled n ...
... experiences were observed in 33 patients. One patient was reported to have chest pain with possible ischemic ECG changes following a single dose of 10 mg. Postmarketing Experience with MAXALT® Serious cardiovascular events have been reported in association with the use of MAXALT®. The uncontrolled n ...
Melatonin Information for Primary Care – Nov 2014
... Avoid - reduces effectiveness of melatonin. May reduce melatonin concentrations. Melatonin may enhance the sedative properties of other drugs acting on the CNS e.g. benzodiazepines. ...
... Avoid - reduces effectiveness of melatonin. May reduce melatonin concentrations. Melatonin may enhance the sedative properties of other drugs acting on the CNS e.g. benzodiazepines. ...
mechanisms of la toxicity
... potential target sites are altered by the increased cardiac output state. Pregnancy results in decreased plasma protein, thereby increasing the free drug concentration in the vascular compartment. Oestrogen and progesterone also appear to alter cardiomyocyte electrophysiology to increase arrhythmo ...
... potential target sites are altered by the increased cardiac output state. Pregnancy results in decreased plasma protein, thereby increasing the free drug concentration in the vascular compartment. Oestrogen and progesterone also appear to alter cardiomyocyte electrophysiology to increase arrhythmo ...
Namenda - Allergan
... donepezil. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer’s disease, the adverse event profile observed with a combination of NAMENDA and donepezil was similar to that of donepezil alone. Effect of NAMENDA on the Metabolism of Other Drugs In vitro studies conduc ...
... donepezil. In a 24-week controlled clinical study in patients with moderate to severe Alzheimer’s disease, the adverse event profile observed with a combination of NAMENDA and donepezil was similar to that of donepezil alone. Effect of NAMENDA on the Metabolism of Other Drugs In vitro studies conduc ...
Pumpinox Esomeprazole Tablets 20mg and 40mg
... 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life (t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged ...
... 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life (t1/2) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged ...
Acute pain management for opioid tolerant patients - e
... Increased opioid consumption For a given procedure, postoperative PCA opioid use has been shown to be 2-3 times higher in opioid tolerant patients compared with opioid naive controls. Increased pain scores This group of patients consistently report higher pain scores and this can make assessment cha ...
... Increased opioid consumption For a given procedure, postoperative PCA opioid use has been shown to be 2-3 times higher in opioid tolerant patients compared with opioid naive controls. Increased pain scores This group of patients consistently report higher pain scores and this can make assessment cha ...
Pycnogenol Monograph - American Botanical Council
... that the occurrence of AEs is unrelated to the dose or duration of use. From what can be gleaned from the clinical trials, it appears that gastrointestinal (GI) discomfort is the most frequently occurring AE. This may be attributed to the astringent nature of Pycnogenol. The GI effects did not occur ...
... that the occurrence of AEs is unrelated to the dose or duration of use. From what can be gleaned from the clinical trials, it appears that gastrointestinal (GI) discomfort is the most frequently occurring AE. This may be attributed to the astringent nature of Pycnogenol. The GI effects did not occur ...
ZYRTEC® (cetirizine hydrochloride) Tablets and
... more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Pediatric Use: The safety of ZYRTEC, at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials las ...
... more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Pediatric Use: The safety of ZYRTEC, at daily doses of 5 or 10 mg, has been demonstrated in 376 pediatric patients aged 6 to 11 years in placebo-controlled trials las ...
Loop diuretics
... : d/t decreased renal perfusion (and therefore decreased drug delivery to the kidney), diminished proximal secretion (d/t the retention of competing anions in renal failure), renal vasoconstriction(cirrhosis), and enhanced activity of sodium-retaining forces (such as the RAAS) ...
... : d/t decreased renal perfusion (and therefore decreased drug delivery to the kidney), diminished proximal secretion (d/t the retention of competing anions in renal failure), renal vasoconstriction(cirrhosis), and enhanced activity of sodium-retaining forces (such as the RAAS) ...
Ketorolac Tromethamine
... hypersensitivity to this drug or other NSAIDs and those patients in whom Aspirin or other prostaglandin synthesis inhibitors induce allergic reactions. It is also contraindicated in a history of peptic ulcer or gastro-intestinal bleeding, moderate or severe renal impairment (serum creatinine> 160 mi ...
... hypersensitivity to this drug or other NSAIDs and those patients in whom Aspirin or other prostaglandin synthesis inhibitors induce allergic reactions. It is also contraindicated in a history of peptic ulcer or gastro-intestinal bleeding, moderate or severe renal impairment (serum creatinine> 160 mi ...
REFERENCE GUIDE FOR THE PHARMACY LICENSING EXAM
... dizziness, depression and mood swings are reported side effects of the drug. 4). Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with Topiramate (Topamax) use. Patients, especially pediatric patients, treated with Topiramate (Topamax) s ...
... dizziness, depression and mood swings are reported side effects of the drug. 4). Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with Topiramate (Topamax) use. Patients, especially pediatric patients, treated with Topiramate (Topamax) s ...
Use of nonsteroidal antiinflammatory drugs in dental practice. A review
... that rank intermediately between corticoids with antiinflammatory properties on one hand, and major analgesics – opioids on the other. Self-medication practices are very common with these drugs, and although they are generally quite safe, some have important side effects such as upper gastrointestin ...
... that rank intermediately between corticoids with antiinflammatory properties on one hand, and major analgesics – opioids on the other. Self-medication practices are very common with these drugs, and although they are generally quite safe, some have important side effects such as upper gastrointestin ...
MDWISE MEDICAL NECESSITY CRITERIA
... The safety and effectiveness in pediatric patients below the age of 6 years have not been established. REFERENCES 1. National Asthma Education and Prevention Program. Expert panel report-3, 2007: Guidelines for the Diagnosis and Management of Asthma. Washington, DC: US Department of Health and Human ...
... The safety and effectiveness in pediatric patients below the age of 6 years have not been established. REFERENCES 1. National Asthma Education and Prevention Program. Expert panel report-3, 2007: Guidelines for the Diagnosis and Management of Asthma. Washington, DC: US Department of Health and Human ...
Article: "Preparing and Dispensing Oral Liquids"
... conducted studies demonstrating that the new system was feasible and that it reduced the potential for error compared with the traditional systems.2 The American Society of Health‐System Pharmacists (ASHP)3 defines unit dose dispensing mainly by its characteristics: “The unit ...
... conducted studies demonstrating that the new system was feasible and that it reduced the potential for error compared with the traditional systems.2 The American Society of Health‐System Pharmacists (ASHP)3 defines unit dose dispensing mainly by its characteristics: “The unit ...
Uprima 2 mg
... elimination half-life of approximately 3 hours. Due to extensive first pass metabolism, Uprima appears to be nearly ineffective when swallowed, with only 1 – 2 % of the activity seen after intravenous or subcutaneous administration. Absorption: apomorphine is rapidly absorbed from the sublingual cav ...
... elimination half-life of approximately 3 hours. Due to extensive first pass metabolism, Uprima appears to be nearly ineffective when swallowed, with only 1 – 2 % of the activity seen after intravenous or subcutaneous administration. Absorption: apomorphine is rapidly absorbed from the sublingual cav ...
Dydrogesterone
Dydrogesterone (INN, USAN, BAN), is also chemically known as 9β,10α-pregna-4,6-diene-3,20-dione. Dydrogesterone (6-dehydro-retroprogesterone) is a hormonally active, non-androgenic steroid that was developed in the 1950s.Dydrogesterone has selective progestational activity and does not inhibit ovulation. The greater rigidity of dydrogesterone also positively affects its selectivity, while natural progesterone is less selective, existing in different conformations that more easily bind to different receptors. As a consequence of its better bioavailability and the progestational activity of its main metabolites (20-, 21- and 16-hydroxy derivatives), the equivalent dose of dydrogesterone is 10–20 times lower than that of oral micronized progesterone.Dydrogesterone is used as an effective, orally active progestogen for gynaecological conditions related to a wide variety of progesterone deficiencies in pregnant women. The molecular structure and pharmacological effects are somewhat similar to endogenous progesterone, although in smaller amounts it is found to be orally active. Its freedom from hormonal effects like those related to corticoid, androgenic, estrogenic, anabolic, and other effects gives dydrogesterone an advantage over other synthesized progestogens.Dydrogesterone when used therapeutically is closely related to its physiological action on the neuro-endocrine control of ovarian function, as well as on the endometrium. This is an indication in all cases of endogeneous progesterone deficiency - relative or absolute. The molecule was licensed for use in several indications, including threatened or recurrent miscarriage, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhoea, irregular cycles, pre-menstrual syndrome and also as a hormone replacement therapy.Dydrogesterone has proven effective in the following conditions associated with progesterone deficiency: Infertility due to luteal insufficiency Threatened miscarriage Habitual or recurrent miscarriage. Menstrual disorders Premenstrual syndrome Endometriosis Dydrogesterone has also been registered as hormone replacement therapy (HRT) to counter-check the negative effects of unopposed estrogen on the endometrium in women with an intact uterus. Dydrogesterone is relatively safe and well tolerated, and does not exhibit the androgenic side effects that are common with some other progestins, like medroxyprogesterone acetate.